2024年8月14日 · Since the establishment of the National Healthcare Security Administration (NHSA) in 2018, the National Reimbursement Drug List (NRDL) has added over 700 emergency, life-saving, and innovative drugs. This blog provides an overview of the NRDL’s history, highlights the key changes for 2024, and discusses the potential impact on both local and ...

2020年1月22日 · In 2019, along with the establishment of numerous reforms, the Chinese government has decided to restore the National Reimbursed Drug List (NRDL). The NRDL is a list of drugs that are authorized by central government agencies for reimbursement. The government will pay back some of the expenses only when the drugs are not as costly.

China's National Reimbursement Drug List (NRDL) is the catalogue of medications covered under the country's public health insurance system. The NRDL aims to enhance healthcare accessibility by subsidizing essential and innovative drugs, thereby …

参比制剂（Reference Listed Drug, RLD） 参比制剂是指作为ANDA申报中参照的FDA指定的已批准药物。 收录在橙皮书中根据505(c)批准的药品均有资格被选做参比制剂。

2024年3月7日 · During the 2023 NRDL adjustment, a total of 25 innovative drugs (including Class 1 chemical drugs, Class 1 therapeutic biological products, and Class 1 and Class 3 traditional Chinese medicines according to the current drug registration management measures and classification standards) participated in the negotiations.

本数据库基于中国NMPA和CDE公布的化学仿制药参比制剂目录制作,提供快捷检索方式和简洁高效的数据呈现,并可追溯数据源。

One of the key factors for selecting applicants and drugs for NRDL negotiation is the clinical value in addressing relevant unmet needs. Experts scored each drug by considering its value in safety, efficacy, economics, innovation, and equity.

Starting January 1, 2024, the Chinese NRDL will add 124 new drugs including 15 drugs for rare diseases, 17 anti-virals including anti-COVID products, 15 drugs for chronic diseases like diabetes, and 23 cancer products. To be eligible to enter the NRDL, almost all of these drug prices were reduced – on average by 61%.

2021年12月8日 · On Dec. 3, China released its 2021 National Reimbursement Drug List (NRDL) 1 and set its implementation date on Jan. 1, 2022. NRDL is a list of drugs allowable for reimbursement by the national social health insurance fund under the social security system which has covered more than 1.36 billion 2 people in China by the end of 2020.

2024年1月1日 · The updated 2023 NRDL includes a total of 3,088 drugs, with 126 new additions and the removal of one drug, Elbasvir and Grazoprevir Tablets. On Dec 13, 2023, China published the 2023 National Reimbursement Drug List (NRDL), which is set to take effect on the first day of 2024.